Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719100 | PMC |
| http://dx.doi.org/10.3324/haematol.2021.280161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.
Clin Infect Dis
March 2025
Merck & Co., Inc., Rahway, NJ, USA.
Background: Doravirine/islatravir is an investigational, once-daily regimen being studied for HIV-1 treatment.
Methods: In this phase 3, double-blind, non-inferiority trial, previously untreated people with HIV-1 (≥18 years) were randomized (1:1) and stratified by HIV-1 RNA (≤/>100,000 copies/mL) and CD4 count ( View Article and Find Full Text PDF
Study on the predictive value of preoperative CT features for the mitotic index of GIST based on the nomogram.
Sci Rep
March 2025
Department of Gastroenteropancreatic & Hernia Surgery, Shanxi Provincial People's Hospital, Shanxi Medical University, Shanxi, 030012, China.
This study aimed to construct a Nomogram based on preoperative CT features to predict the mitotic index in gastrointestinal stromal tumors and to establish preoperative risk stratification. The constructed nomogram prediction model is targeted towards guiding preoperative risk stratification, facilitating the provision of rational drug administration regimens, and tailoring appropriate surgical plans for personalized treatment. The imaging and pathological data of 250 patients with gastrointestinal stromal tumors in Shanxi Provincial hospital from January 2019 to January 2024 were retrospectively analyzed.
View Article and Find Full Text PDFNomogram for Predicting Pathological Complete Response after Neoadjuvant Chemotherapy in Operable Primary Breast Cancer.
J Coll Physicians Surg Pak
March 2025
Breast Centre, Shunyi District Health Care Hospital for Women and Children of Beijing, Beijing, China.
Objective: To establish a predictive model for pathological complete response (pCR) in operable primary breast cancer after neoadjuvant chemotherapy (NAC).
Study Design: Observational study. Place and Duration of the Study: Breast Centre, Shunyi District Health Care Hospital for Women and Children of Beijing, Beijing, China, from January 2010 to June 2023.
SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions.
Clin Lymphoma Myeloma Leuk
February 2025
Department of Leukemia, MD Anderson Cancer Center, Houston, TX. Electronic address:
Advances in understanding leukemogenesis in acute myeloid leukemia (AML) have led to new drug approvals in the past 4 years. Ongoing preclinical research is expected to produce more targeted therapies, reducing the need for traditional chemotherapy, while also enhancing classification systems and patient prognostication. In newly diagnosed AML, the mainstay of induction still is 7+3 regimen.
View Article and Find Full Text PDFRatifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach.
Intern Med J
March 2025
Monash Haematology, Monash Health, Melbourne, Victoria, Australia.
Background: After pharmaceutical benefits scheme approval of midostaurin for fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline) to align with future clinical trial protocols.
Aims: To determine the efficacy and safety of idarubicin-based 7+3 induction ± midostaurin (per ALLG recommendations) in a real-world, tertiary hospital setting.
Methods: Data were prospectively collected for all patients assessed for front-line AML treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!